The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On April 6, Opus Genetics signed a strategic financing agreement with Oberland Capital worth up to $155 million. The financing includes a $35 million upfront payment and a $5 million equity investment, extending the company's cash runway into 2029. Funds will be used to accelerate gene therapy programs for inherited retinal diseases and support upcoming clinical trials.